Last reviewed · How we verify
Dicloxacillin Oral Capsule
At a glance
| Generic name | Dicloxacillin Oral Capsule |
|---|---|
| Also known as | Elocon (Mometasone furoate 0.1%) |
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dicloxacillin Oral Capsule CI brief — competitive landscape report
- Dicloxacillin Oral Capsule updates RSS · CI watch RSS
- Fundacion Clinic per a la Recerca Biomédica portfolio CI